Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Payables (2016 - 2025)

Viking Therapeutics' Payables history spans 12 years, with the latest figure at $53.3 million for Q4 2025.

  • For Q4 2025, Payables rose 442.66% year-over-year to $53.3 million; the TTM value through Dec 2025 reached $53.3 million, up 442.66%, while the annual FY2025 figure was $53.3 million, 442.66% up from the prior year.
  • Payables for Q4 2025 was $53.3 million at Viking Therapeutics, up from $4.4 million in the prior quarter.
  • Across five years, Payables topped out at $53.3 million in Q4 2025 and bottomed at $254000.0 in Q3 2024.
  • The 5-year median for Payables is $5.4 million (2024), against an average of $7.7 million.
  • The largest annual shift saw Payables tumbled 95.55% in 2024 before it soared 1637.4% in 2025.
  • A 5-year view of Payables shows it stood at $1.4 million in 2021, then skyrocketed by 490.65% to $8.5 million in 2022, then dropped by 11.92% to $7.5 million in 2023, then skyrocketed by 30.63% to $9.8 million in 2024, then skyrocketed by 442.66% to $53.3 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Payables are $53.3 million (Q4 2025), $4.4 million (Q3 2025), and $5.5 million (Q2 2025).